This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Hepatitis B
and you are
between 18 and 50
years old
-
The phase for this study is not defined.
Show me locations

The purpose

For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In the investigators study, patients were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.

Provided treatments

  • Drug: Entecavir
  • Drug: Peginterferon alfa-2a
Tris trial is registered with FDA with number: NCT01599130. The sponsor of the trial is Sun Yat-sen University and it is looking for 60 volunteers for the current phase.
Official trial title:
The Efficacy of Peg-interferon α-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss